The earnings call reflected a balanced outlook. While Delcath Systems showcased strong revenue growth, positive cash flow, and strategic expansion of treating sites, challenges such as slower site activations and increased expenses were noted. Adjustments in financial guidance due to the 340B program also posed potential challenges. However, the company's proactive initiatives in R&D and pipeline expansion position it well for future growth.

Company Guidance -

Q3 2025

During the Delcath Systems Second Quarter 2025 Earnings Call, the company provided updated guidance reflecting their business progress and future expectations. Quarterly revenue reached $24.2 million, marking a more than 20% increase compared to the previous quarter, with U.S. sales of HEPZATO at $22.5 million and CHEMOSAT sales in Europe at $1.7 million. The company generated $7.3 million in positive cash from operations and reported a net income of $2.7 million, alongside an adjusted EBITDA of $9.8 million. Delcath ended the quarter with no debt and approximately $81 million in cash and investments. The company adjusted its full-year revenue guidance to $93 million to $96 million due to slower U.S. site activations, while maintaining projections for 83% to 85% gross margins and continued positive non-GAAP adjusted EBITDA. The total HEPZATO treatment volume for 2025 is expected to increase by over 175% compared to 2024. Delcath plans to expand to 25 to 28 operational centers by the end of the fourth quarter, anticipating 40 sites by the end of 2026. The company also discussed future clinical trials, including those for liver-dominant metastatic colorectal and breast cancer, with trials anticipating interim data releases beginning in 2027.

Significant Revenue Growth

Quarterly revenue reached $24.2 million, an increase of over 20% compared to the first quarter of 2025, with U.S. sales of HEPZATO contributing $22.5 million.

Positive Financial Performance

Generated $7.3 million in positive cash from operations, net income of $2.7 million, and adjusted EBITDA of $9.8 million. The company ended the quarter with no debt and approximately $81 million in cash and investments.

Expansion of Treating Sites

Activated Northwestern Memorial Hospital, University of Miami Hospital, and the University of Virginia Medical Center. 20 treating sites were active by the end of the second quarter, with expectations to reach 25 to 28 operational centers by the end of the fourth quarter.

R&D and Pipeline Expansion

Initiated company-sponsored trials in liver-dominant metastatic colorectal cancer and liver-dominant metastatic breast cancer, with FDA clearance and CTA authorization in Europe and the U.K.

Successful Financial Management

Gross margins increased to 86% from 80% in the prior year. Non-GAAP positive adjusted EBITDA of $9.8 million compared to a loss of $0.8 million in 2024.

Delcath Systems (DCTH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DCTH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	-0.04 / -	0.06	―	―	―
Aug 06, 2025	2025 (Q2)	0.03 / 0.07	-0.48	114.58% (+0.55)	―
May 08, 2025	2025 (Q1)	0.02 / 0.03	-0.45	106.67% (+0.48)	―
Mar 06, 2025	2024 (Q4)	>-0.01 / -0.11	-0.48	77.08% (+0.37)	―
Nov 08, 2024	2024 (Q3)	-0.20 / 0.06	-1.14	105.26% (+1.20)	―
Aug 05, 2024	2024 (Q2)	-0.36 / -0.48	-0.58	17.24% (+0.10)	―
May 14, 2024	2024 (Q1)	-0.45 / -0.45	-0.77	41.56% (+0.32)	―
Mar 26, 2024	2023 (Q4)	-0.54 / -0.48	-0.86	44.19% (+0.38)	―
Nov 13, 2023	2023 (Q3)	-0.52 / -1.14	-0.92	-23.91% (-0.22)	―
Aug 09, 2023	2023 (Q2)	-0.51 / -0.58	-1.18	50.85% (+0.60)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DCTH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$10.52	$10.64	+1.14%
May 08, 2025	$11.61	$14.36	+23.69%
Mar 06, 2025	$13.43	$13.22	-1.56%
Nov 08, 2024	$10.94	$11.06	+1.10%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Delcath Systems (DCTH) report earnings?

Delcath Systems (DCTH) is schdueled to report earning on Nov 11, 2025, TBA (Confirmed).

What is Delcath Systems (DCTH) earnings time?

Delcath Systems (DCTH) earnings time is at Nov 11, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is DCTH EPS forecast?

DCTH EPS forecast for the fiscal quarter 2025 (Q3) is -0.04.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing